These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23027415)

  • 21. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
    Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of 5-HT(2C) mediated mechanisms involved in urethral sphincter reflexes in a guinea-pig model of urethral function.
    Conlon K; Miner W; McCleary S; McMurray G
    BJU Int; 2012 Jul; 110(2 Pt 2):E113-7. PubMed ID: 22192599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
    Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
    Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
    Adams W; van den Buuse M
    Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade.
    Fletcher PJ; Rizos Z; Noble K; Higgins GA
    Neuropharmacology; 2011 Sep; 61(3):468-77. PubMed ID: 21402085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin control of sleep-wake behavior.
    Monti JM
    Sleep Med Rev; 2011 Aug; 15(4):269-81. PubMed ID: 21459634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
    Higgins GA; Sellers EM; Fletcher PJ
    Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ; Wacker DA
    Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
    Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
    Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
    Shen JH; Zhao Y; Rosenzweig-Lipson S; Popp D; Williams JB; Giller E; Detke MJ; Kane JM
    J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.
    Cheng J; Kozikowski AP
    ChemMedChem; 2015 Dec; 10(12):1963-7. PubMed ID: 26507582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of 5-HT2C receptors in affective disorders.
    Jenck F; Bös M; Wichmann J; Stadler H; Martin JR; Moreau JL
    Expert Opin Investig Drugs; 1998 Oct; 7(10):1587-99. PubMed ID: 15991903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonergic mechanisms as targets for existing and novel antipsychotics.
    Meltzer HY
    Handb Exp Pharmacol; 2012; (212):87-124. PubMed ID: 23129329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.